Literature DB >> 24166215

Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia.

C Récher1, M C Béné2, B Lioure3, A Pigneux4, N Vey5, J Delaunay6, I Luquet7, M Hunault8, D Guyotat9, D Bouscary10, N Fegueux11, E Jourdan12, S Lissandre13, M Escoffre-Barbe14, C Bonmati15, E Randriamalala16, R Guièze17, M Ojeda-Uribe18, F Dreyfus10, J L Harousseau19, J Y Cahn20, N Ifrah8, P Guardiola8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24166215     DOI： 10.1038/leu.2013.290

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Cytarabine dose for acute myeloid leukemia.

Authors:  Bob Löwenberg; Thomas Pabst; Edo Vellenga; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Bart J Biemond; Alois Gratwohl; Georgine E de Greef; Leo F Verdonck; Martijn R Schaafsma; Michael Gregor; Matthias Theobald; Urs Schanz; Johan Maertens; Gert J Ossenkoppele
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

2.  Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.

Authors:  Shigeki Ohtake; Shuichi Miyawaki; Hiroyuki Fujita; Hitoshi Kiyoi; Katsuji Shinagawa; Noriko Usui; Hirokazu Okumura; Koichi Miyamura; Chiaki Nakaseko; Yasushi Miyazaki; Atsushi Fujieda; Tadashi Nagai; Takahisa Yamane; Masafumi Taniwaki; Masatomo Takahashi; Fumiharu Yagasaki; Yukihiko Kimura; Norio Asou; Hisashi Sakamaki; Hiroshi Handa; Sumihisa Honda; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal:  Blood       Date:  2010-08-06       Impact factor: 22.113

Review 3.  Optimal induction and post-remission therapy for AML in first remission.

Authors:  Jacob M Rowe
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

4.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

5.  Anthracycline dose intensification in acute myeloid leukemia.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

6.  Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

Authors:  Claude Gardin; Sylvie Chevret; Cécile Pautas; Pascal Turlure; Emmanuel Raffoux; Xavier Thomas; Bruno Quesnel; Thierry de Revel; Stéphane de Botton; Nathalie Gachard; Aline Renneville; Nicolas Boissel; Claude Preudhomme; Christine Terré; Pierre Fenaux; Dominique Bordessoule; Karine Celli-Lebras; Sylvie Castaigne; Hervé Dombret
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

7.  Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

Authors:  Franco Mandelli; Marco Vignetti; Stefan Suciu; Roberto Stasi; Maria-Concetta Petti; Giovanna Meloni; Petra Muus; Filippo Marmont; Jean-Pierre Marie; Boris Labar; Xavier Thomas; Francesco Di Raimondo; Roel Willemze; Vincenzo Liso; Felicetto Ferrara; Liliana Baila; Paola Fazi; Robert Zittoun; Sergio Amadori; Theo de Witte
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

8.  Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.

Authors:  P H Wiernik; P L Banks; D C Case; Z A Arlin; P O Periman; M B Todd; P S Ritch; R E Enck; A B Weitberg
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

Review 9.  Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis.

Authors:  Oliver Teuffel; Kurt Leibundgut; Thomas Lehrnbecher; Todd A Alonzo; Joseph Beyene; Lillian Sung
Journal:  Br J Haematol       Date:  2013-02-08       Impact factor: 6.998

Review 10.  Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.

Authors:  Giorgio Minotti; Pierantonio Menna; Emanuela Salvatorelli; Gaetano Cairo; Luca Gianni
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468
View more
  8 in total

Review 1.  Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.

Authors:  Sunil Adige; Rena G Lapidus; Brandon A Carter-Cooper; Alison Duffy; Ciera Patzke; Jennie Y Law; Maria R Baer; Nicholas P Ambulos; Ying Zou; Søren M Bentzen; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2019-04-09       Impact factor: 3.333

2.  Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis.

Authors:  Yiqing Li; Ting Tang; Jie Xiao; Boqi Li; Wenjuan Yang; Shuangfeng Xie; Yumo Du; Kezhi Huang; Danian Nie
Journal:  Ann Hematol       Date:  2022-04-20       Impact factor: 3.673

3.  Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia.

Authors:  Qingguo Liu; Hongye Gao; Junfan Li; Yimin Hu; Lihua Wu; Xin Zhao; Shangzhu Li
Journal:  EJHaem       Date:  2020-08-11

4.  A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.

Authors:  Alan K Burnett; Nigel H Russell; Robert K Hills; Jonathan Kell; Jamie Cavenagh; Lars Kjeldsen; Mary-Frances McMullin; Paul Cahalin; Mike Dennis; Lone Friis; Ian F Thomas; Don Milligan; Richard E Clark
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

5.  Improved outcome for AML patients over the years 2000-2014.

Authors:  Sarah Bertoli; Suzanne Tavitian; Anne Huynh; Cécile Borel; Sarah Guenounou; Isabelle Luquet; Eric Delabesse; Audrey Sarry; Guy Laurent; Michel Attal; Françoise Huguet; Emilie Bérard; Christian Récher
Journal:  Blood Cancer J       Date:  2017-11-29       Impact factor: 11.037

6.  Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia.

Authors:  Juan Eduardo Megías-Vericat; David Martínez-Cuadrón; Joaquín Martínez López; Juan Miguel Bergua; Mar Tormo; Josefina Serrano; Ataulfo González; Jaime Pérez de Oteyza; Susana Vives; Belén Vidriales; Pilar Herrera; Juan Antonio Vera; Aurelio López Martínez; Adolfo de la Fuente; Ma Lourdes Amador; José-Ángel Hernández-Rivas; Ma Ángeles Fernández; Carlos Javier Cerveró; Daniel Morillo; Pilar Hernández Campo; Julián Gorrochategui; Daniel Primo; José Luis Rojas; Margarita Guenova; Joan Ballesteros; Miguel Sanz; Pau Montesinos
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-03-01       Impact factor: 2.576

7.  Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience.

Authors:  Sarah Bertoli; Suzanne Tavitian; Pierre Bories; Isabelle Luquet; Eric Delabesse; Thibault Comont; Audrey Sarry; Françoise Huguet; Emilie Bérard; Christian Récher
Journal:  Cancer Med       Date:  2019-06-07       Impact factor: 4.452

8.  Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L.

Authors:  Safiullah Najem; Doerte Langemann; Birgit Appl; Magdalena Trochimiuk; Patrick Hundsdoerfer; Konrad Reinshagen; Georg Eschenburg
Journal:  Oncotarget       Date:  2016-11-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.